|
Mechanismalpha-tubulin inhibitors [+1] |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date01 Jan 1989 |
评价注射用酒石酸长春瑞滨胶束在晚期实体瘤患者中单次给药和多次给药安全性和耐受性的研究
[Translation] A study to evaluate the safety and tolerability of single and multiple administrations of vinorelbine tartrate micelles for injection in patients with advanced solid tumors
主要目的: 1. 评价注射用酒石酸长春瑞滨胶束在晚期实体瘤患者中单次给药和多次给药的安全性和耐受性、药代动力学特征。 次要目的: 评价注射用长春瑞滨胶束在晚期恶性实体瘤患者中的初步疗效,为后 期临床试验的给药方案提供理论依据。
[Translation] Primary objective: 1. To evaluate the safety, tolerability and pharmacokinetic characteristics of single and multiple administrations of vinorelbine tartrate micelles for injection in patients with advanced solid tumors. Secondary objective: To evaluate the preliminary efficacy of vinorelbine micelles for injection in patients with advanced malignant solid tumors and provide a theoretical basis for the dosing regimen of subsequent clinical trials.
100 Clinical Results associated with Beijing Diacrid Medical Technology Co Ltd
0 Patents (Medical) associated with Beijing Diacrid Medical Technology Co Ltd
100 Deals associated with Beijing Diacrid Medical Technology Co Ltd
100 Translational Medicine associated with Beijing Diacrid Medical Technology Co Ltd